In This Article:
Over the last 7 days, the Australian market has remained flat, but it is up 22% over the past year with earnings forecast to grow by 12% annually. In light of these conditions, investors may find value in exploring stocks that combine affordability with growth potential. Penny stocks—often representing smaller or newer companies—can offer such opportunities when they are backed by strong financial health.
Top 10 Penny Stocks In Australia
Name | Share Price | Market Cap | Financial Health Rating |
LaserBond (ASX:LBL) | A$0.57 | A$65.06M | ★★★★★★ |
Embark Early Education (ASX:EVO) | A$0.795 | A$128.44M | ★★★★☆☆ |
MaxiPARTS (ASX:MXI) | A$1.825 | A$104.82M | ★★★★★★ |
Austin Engineering (ASX:ANG) | A$0.50 | A$310.07M | ★★★★★☆ |
Helloworld Travel (ASX:HLO) | A$1.85 | A$300.41M | ★★★★★★ |
Navigator Global Investments (ASX:NGI) | A$1.70 | A$842.94M | ★★★★★☆ |
West African Resources (ASX:WAF) | A$1.715 | A$1.95B | ★★★★★★ |
Atlas Pearls (ASX:ATP) | A$0.135 | A$56.64M | ★★★★★★ |
GTN (ASX:GTN) | A$0.47 | A$92.11M | ★★★★★★ |
Joyce (ASX:JYC) | A$3.90 | A$115.92M | ★★★★★★ |
Click here to see the full list of 1,027 stocks from our ASX Penny Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Artrya
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Artrya Limited is a medical technology company focused on developing and commercialising an artificial intelligence platform for detecting, diagnosing, and addressing coronary artery disease in Australia, with a market cap of A$35.42 million.
Operations: Currently, there are no reported revenue segments for Artrya Limited.
Market Cap: A$35.42M
Artrya Limited, with a market cap of A$35.42 million, is currently pre-revenue and unprofitable, having reported a net loss of A$14 million for the year ending June 2024. The company has no debt but faces financial challenges with less than a year of cash runway based on current free cash flow. Its short-term assets exceed both short- and long-term liabilities, providing some balance sheet strength. However, the board's average tenure is relatively low at 2.2 years, indicating inexperience. The stock has shown high volatility recently and earnings have declined significantly over the past five years.
-
Navigate through the intricacies of Artrya with our comprehensive balance sheet health report here.
-
Gain insights into Artrya's historical outcomes by reviewing our past performance report.
Li-S Energy
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Li-S Energy Limited focuses on the development and commercialization of lithium sulphur and metal batteries in Australia, with a market cap of A$69.98 million.
Operations: Li-S Energy Limited does not have any reported revenue segments at this time.